SVP of Research. In addition to its TRACER capsid-discovery platform, Voyager has developed a strategy to accelerate the development of an AAV–glucocerebrosidase 1 (GBA1) gene replacement ...

SVP for program development and operations at Chameleon. “Our EVADER platform delivers therapies that significantly reduce the immunogenic burden typically seen with AAV-based therapies and thus ...